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Inclusion Criteria:
• All patients who received 4-factor PCC at the
study institution
Dates:
• March 1, 2018 to August 31, 2018
Data Collected:
• Patient demographics: (sex, age, height,
weight, BMI)
• Drug reversed
• Indication for anticoagulation
• Location of bleed
• Dose administered
• Baseline and follow-up INR, PT and PTT as
appropriate
• Other factors or blood products utilized
• Surgical or procedural interventions required
POSTER ID: 11-256
• 4-factor PCC is a single agent indicated for the 
urgent reversal of acquired coagulation factor 
deficiency induced by vitamin K antagonist 
therapy, such as warfarin, in adult patients with 
need for urgent surgery, invasive procedure or 
acute major bleeding. It is also used off-label 
with limited data for the reversal of life-
threatening hemorrhage associated with non-
vitamin K antagonist anticoagulation
• Currently at our hospital, there is an established 
protocol for 4-factor PCC in the setting of 
warfarin reversal, but not for non-warfarin 
reversal
• The purpose of this study was to evaluate 
appropriate usage of 4-factor PCC based on 
indication and dosage in patients requiring 
urgent anticoagulation reversal
Gender Average 
Age
Average 
BMI
Anticoagulation 
Indication
Agent 
Reversed
Location of 
Bleed
Warfarin 
Reversal 
Group 
(n=6)
Male 67%
Female 
33%
78
(Range 62-
97)
25
(Range 
22.8-27.7)
Atrial fibrillation
50%
Clotting disorder
17%
History of stroke 
17%
Mechanical valve 
17%
Warfarin 
100%
ICH 67%
GIB 0%
Other 33%
(1 CSF, 1 
rectal)
Non-
warfarin 
Reversal 
Group 
(n=7)
Male 43%
Female 
57%
81
(Range 67-
96)
31
(Range 
23.2-42.9)
Atrial fibrillation 
71%
DVT 14%
PE 14%
Apixaban
43%
Rivaroxaban
57%
ICH 57%
GIB 0%
Other 43%
(1 vaginal, 1 
rectal, 1 
pelvic)
Table 1. Patient Demographics
Vitamin K Given Blood Products Given Surgery/Procedure
Warfarin Reversal 
Group
(n=6)
Yes 100%
No 0%
Yes 0%
No 100%
Yes 17%
No 83%
Non-warfarin 
Reversal Group
(n=7)
Yes 14%
No 86%
Yes 43%
No 57%
Yes 29%
No 71%
Table 3. Other Treatment Received
Based on the results, we conclude that 4-factor PCC
was appropriately indicated in 100% of the cases
between March 1, 2018 to August 31, 2018.
4-factor PCC was correctly dosed in 54% of total
patients included in the review
• 83% of warfarin reversals
• 29% of non-warfarin reversals
4-factor PCC was mostly used for the reversal of
non-warfarin agents, such as direct oral
anticoagulants (DOACs) with the exception of
dabigatran
• 54% of the cases involved DOACs
• 46% of the cases involved warfarin
Comparison of baseline, post treatment, and average
levels show an improvement of INR for warfarin
• Minimal changes in PT and PTT for apixaban and
rivaroxaban
The overall mortality rate of patients receiving 4-
factor PCC in our sample was 15%
Overall, we see the need for developing a protocol
for non-warfarin reversal at our institution to facilitate
choosing the correct dosages in life-threatening
bleeds. We also recommend adding reversal agents
for individual DOACs as they become available.
Pre-
Treatment 
INR
Post-
Treatment 
INR
Average 
Pre-
Treatment 
PT
Average 
Post-
Treatment 
PT
Average 
Pre-
Treatment 
PTT
Average 
Post-
Treatme
nt PTT
Warfarin 
Reversal 
Group (n=6)
<2 (17%)
2 to <4 (67%)
4 to 6 (0%)
>6 (17%)
<2 (100%) 43.2
(Range 19.7-
120)
15.2
(Range 13.5-
19.6)
63.7
(Range 30-
183)
29
(5 not 
reported)
Non-
warfarin 
Reversal 
Group (n=7)
<2 (57%)
2 to <4 (29%)
4 to 6 (0%)
>6 (0%)
Not reported 
(14%)
<2 (57%)
Not reported 
(43%)
21.8
(Range 16.9-
29.1)
(1 not 
reported)
15.9
(Range 15.2-
17.3)
(3 not 
reported)
42.4
(Range 35-
60)
(2 not 
reported)
None 
reported
Table 2. Summary of Coagulation Assays
